# DESCRIPTION

## BACKGROUND OF THE INVENTION

- relate to recombinant DNA technology
- motivate need for cancer treatment
- describe alphavirus genus
- summarize alphavirus structure
- discuss alphavirus vectors
- mention prior art
- state need for melanoma treatment

## BRIEF SUMMARY OF THE INVENTION

- introduce method of enhancing immune response
- describe pharmaceutical composition
- specify TRP2 amino acid sequence
- outline methods of preventing melanoma
- describe administration routes
- introduce pharmaceutical composition

## DETAILED DESCRIPTION OF THE INVENTION

- introduce need for melanoma treatment
- describe RNA replicon vector system
- motivate humoral and cellular immune responses
- summarize immunization protocols
- discuss melanocyte differentiation antigens
- introduce alphavirus replicon vector system
- describe VRP vaccines
- motivate TRP2 protein
- discuss syngeneic and allogeneic administration
- analyze efficacies of VEE VRP compositions
- discuss role of humoral responses
- describe induction of TRP-2 specific IgG
- discuss CD8+ T-cell response
- summarize synergistic activation of IgGs and CD8+ T cells
- discuss combination with surgery and/or chemotherapeutic approaches
- introduce heterologous prime-boost immunization strategy
- describe forms of antigen administration
- discuss need for improvements in melanoma treatment
- describe ARP expressing TRP2 as immunogens
- discuss procedures for making TRP2-expressing VRP
- summarize VRP vaccine characteristics
- discuss optimal dose determination
- define abbreviations
- define alphavirus
- describe 5' and 3' alphavirus replication recognition sequences
- define minimal 5' alphavirus replication recognition sequence
- describe alphavirus RNA replicon
- define helper constructs
- describe helper cells
- define alphavirus replicon particles
- describe promoter for directing transcription
- describe transcription regulatory sequence
- describe IRES element
- describe RNA helper embodiments
- describe DNA helper embodiments
- describe promoters for in vitro transcription
- describe promoters for in vivo transcription
- describe control of nucleic acid expression
- describe IRES elements
- define amino acid abbreviations
- describe expression directed by a sequence
- describe alphavirus-permissive cells
- define structural protein
- describe distribution of structural proteins
- describe deletion of structural proteins
- define replication defective
- describe alphavirus particle production
- describe helper nucleic acid molecules
- describe replicon nucleic acid
- describe alphavirus structural proteins
- describe E1 and E2 glycoproteins
- describe E3 and 6k proteins
- describe polyprotein synthesis
- describe membrane translocation/transport signals
- describe alphavirus particle composition
- describe lipid envelope
- describe nucleocapsid structure
- describe alphavirus particle infectivity
- describe helper cell requirements
- define alphavirus structural proteins
- describe first helper RNA embodiments
- describe second helper RNA embodiments
- describe helper nucleic acid sequences
- describe introduction of RNA helpers into cells
- describe single DNA molecule helper
- describe electroporation-based introduction methods
- describe attenuating mutations
- describe identifying attenuating mutations
- describe attenuating mutations in VEE
- describe attenuating mutations in S.A. AR86
- describe introducing attenuating mutations into RNA
- describe site-directed mutagenesis
- describe replacement of homologous restriction fragments
- describe mutagenic polymerase chain reaction methods
- describe preparation of infective ARPs
- describe TRP2 protein
- describe human melanoma antigen sequences
- describe mouse coding and amino acid sequences
- describe human sequences encoding TRP2
- describe substantially similar sequences
- describe conservative amino substitutions
- describe calculating percent identity
- describe degeneracy of the genetic code
- describe codon usage
- describe allelic variations
- describe immunologically equivalent sequences
- describe standard techniques for cloning and DNA isolation
- describe pharmaceutical formulations
- describe immunogenic amounts
- describe pharmaceutically acceptable carriers
- describe administration methods
- describe subjects for administration
- describe formulation of immunogenic compositions
- describe lyophilized preparations
- describe vaccine composition
- list adjuvants
- motivate adjuvant effectiveness
- describe dosage formulation
- specify dosage range
- describe administration schedule
- motivate multiple dosing regimen
- incorporate prior art references
- exclude prior art embodiments
- describe VRP formulation preparation
- specify compound naming conventions
- describe protein and gene variants
- motivate method equivalencies
- define "comprising"
- define "consisting of"
- define "consisting essentially of"
- describe invention scope
- motivate modification and variation
- describe physician's role in treatment
- describe dosage adjustment
- describe treatment strategy
- list additional treatments
- describe formulation and administration techniques
- list routes of administration
- describe pharmaceutical carrier use
- describe pharmaceutical composition manufacturing
- describe scope of invention

### Murine TRP-2 Cloning

- amplify murine TRP-2 gene

### Replicon Production

- generate pERK3-murine TRP-2 replicon vector

### VRP Production

- package TRP2-expressing replicon
- describe bipartite RNA helper system
- produce VRP using electroporation

### Human TRP-2 Viral Replicon Particles

- generate pERK3-humanTRP-2 replicon vector

### Mice and Cell Lines.

- describe mouse strains
- describe cell lines
- describe vaccination protocol
- describe tumor protection experiments
- describe T cell depletion experiments

### ELISPOT and T-Cell Assays

- describe ELISPOT assay
- describe flow cytometry based intracellular staining assays

### ELISA

- describe ELISA protocol
- analyze TRP2-specific total IgGs

### Analysis of the Tumor Infiltrate

- describe tumor infiltrate analysis
- describe cell staining and analysis

